Mechanism of Action and Safety of Lokelma

Mechanism of Action in the Gastrointestinal Tract

• Lokelma works throughout both the small and large intestines, binding potassium and increasing fecal potassium excretion, which may affect a larger surface area 1
• Unlike other potassium binders that work primarily in the colon, Lokelma acts throughout the GI tract 1

Clinical Evidence and Comparison with Other Potassium Binders

• In randomized trials, Lokelma has not been associated with serious adverse events in the gastrointestinal tract, according to the Mayo Clinic Proceedings 2, 3, 4
• Unlike sodium polystyrene sulfonate (SPS), which has been associated with intestinal necrosis, Lokelma has not shown this specific risk in clinical trials, as reported by the Mayo Clinic Proceedings 1
• The most common adverse effects of Lokelma are hypokalemia and dose-dependent edema, rather than direct gastrointestinal injury, as noted in the Mayo Clinic Proceedings 2, 3